{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:31:11Z","timestamp":1793946671802,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020872","name":"Tainan Municipal An Nan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["ANHRF114-39"],"award-info":[{"award-number":["ANHRF114-39"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.diabres.2026.113236","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:48:34Z","timestamp":1775180914000},"page":"113236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of SGLT2 inhibitors with hematologic malignancies in type 2 diabetes: a target trial emulation study"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-0970","authenticated-orcid":false,"given":"Yuan-Tsung","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Sung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mita","family":"Restinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-8908","authenticated-orcid":false,"given":"Chung-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113236_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137476","article-title":"Associations between diabetes mellitus and selected cancers","volume":"25","author":"Pliszka","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2026.113236_b0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc23-0386","article-title":"Association between age at diabetes diagnosis and subsequent incidence of cancer: a longitudinal population-based Cohort","volume":"47","author":"Li","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2026.113236_b0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00125-020-05338-7","article-title":"Association between diabetes and haematological malignancies: a population-based study","volume":"64","author":"Gong","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2026.113236_b0020","series-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","article-title":"Association of obesity and type 2 diabetes with non-hodgkin lymphoma: the multiethnic cohort","author":"Maskarinec","year":"2023"},{"issue":"1","key":"10.1016\/j.diabres.2026.113236_b0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.diabet.2019.04.006","article-title":"Association between type 1 and type 2 diabetes and risk of non-Hodgkin's lymphoma: a meta-analysis of cohort studies","volume":"46","author":"Wang","year":"2020","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2026.113236_b0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1507\/endocrj.EJ20-0138","article-title":"The association between type 1 and 2 diabetes mellitus and the risk of leukemia: a systematic review and meta-analysis of 18 cohort studies","volume":"68","author":"Yan","year":"2021","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.diabres.2026.113236_b0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4093\/dmj.2020.0250","article-title":"Hyperinsulinemia in obesity, inflammation, and cancer","volume":"45","author":"Zhang","year":"2021","journal-title":"Diabetes Metab J"},{"issue":"4","key":"10.1016\/j.diabres.2026.113236_b0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/endrev\/bnad005","article-title":"Insulin\/IGF axis and the receptor for advanced glycation end products: role in meta-inflammation and potential in cancer therapy","volume":"44","author":"Vella","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.diabres.2026.113236_b0045","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. the","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113236_b0050","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control","volume":"20","author":"O'Hara","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1016\/j.diabres.2026.113236_b0055","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s40618-024-02351-0","article-title":"Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis","volume":"47","author":"Xu","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.diabres.2026.113236_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110621","article-title":"Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials","volume":"198","author":"Spiazzi","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"10.1016\/j.diabres.2026.113236_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/biom15111622","article-title":"Divergent risks of hematologic malignancies associated with GLP-1 receptor agonists and SGLT2 inhibitors: preliminary findings from a pilot network meta-analysis","volume":"15","author":"Lin","year":"2025","journal-title":"Biomolecules"},{"issue":"18","key":"10.1016\/j.diabres.2026.113236_b0070","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical Reanalysis of the Mechanisms underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2026.113236_b0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00395-024-01059-9","article-title":"Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond","volume":"120","author":"Camilli","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.diabres.2026.113236_b0080","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/13543784.2022.2113056","article-title":"Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants","volume":"31","author":"Li","year":"2022","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.diabres.2026.113236_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003550","article-title":"Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study","volume":"11","author":"Pradhan","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.diabres.2026.113236_b0090","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250302","article-title":"Immunomodulatory activity of dipeptidyl peptidase\u20104 inhibitors in immune\u2010related diseases","volume":"53","author":"Drakul","year":"2023","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.diabres.2026.113236_b0095","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2268257","article-title":"Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration","volume":"12","author":"Tian","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.diabres.2026.113236_b0100","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113236_b0105","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113236_b0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2023.0610","article-title":"Risk of new retinal vascular occlusion after mRNA COVID-19 vaccination within aggregated electronic health record data","author":"Dorney","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113236_b0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-022-00692-8","article-title":"Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network","volume":"12","author":"Sanz","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.diabres.2026.113236_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.diabres.2026.113236_b0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Internal Med"},{"key":"10.1016\/j.diabres.2026.113236_b0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"Comparing effectiveness and safety of SGLT2 Inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels","volume":"183","author":"D'Andrea","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabres.2026.113236_b0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079475","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113236_b0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-021-01454-z","article-title":"Oversampling and replacement strategies in propensity score matching: a critical review focused on small sample size in clinical settings","volume":"21","author":"Bottigliengo","year":"2021","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.diabres.2026.113236_b0145","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4143\/crt.2023.1118","article-title":"Association of immune-related adverse events and the efficacy of anti\u2013PD-(L)1 monotherapy in non\u2013small cell lung cancer: adjusting for immortal-time bias","volume":"56","author":"Yu","year":"2024","journal-title":"Cancer Res Treatment : Off J Korean Cancer Assoc"},{"key":"10.1016\/j.diabres.2026.113236_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2023.09.014","article-title":"Key concepts in clinical epidemiology: the use of the E-value for sensitivity analysis","author":"Chung","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.diabres.2026.113236_b0155","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251338669","article-title":"Nonlinear associations of serum vitamin D levels with advanced liver disease and mortality: a US Cohort Study","volume":"18","author":"Tseng","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"10.1016\/j.diabres.2026.113236_b0160","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113236_b0165","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/pds.5623","article-title":"Pragmatic considerations for negative control outcome studies to guide non-randomized comparative analyses: a narrative review","volume":"32","author":"Levintow","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabres.2026.113236_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103749","article-title":"Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records","volume":"91","author":"Irons","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.diabres.2026.113236_b0175","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113236_b0180","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.diabres.2026.113236_b0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-06036-z","article-title":"PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6","volume":"14","author":"Jia","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.diabres.2026.113236_b0190","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2026.113236_b0195","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2026.113236_b0200","first-page":"18","article-title":"Core concepts in pharmacoepidemiology: key biases arising in pharmacoepidemiologic studies","volume":"32","author":"Acton","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:59:12Z","timestamp":1793944752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726001555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S0168822726001555"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113236","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of SGLT2 inhibitors with hematologic malignancies in type 2 diabetes: a target trial emulation study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113236"}}